Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

Clinical Pharmacokinetics

Volumn 44, Issue 4, 2005, Pages 331-347

  Mahmood, Iftekhar ^a,b   Green, Martin D ^a  

^a Center for Drug Evaluation and Research   (United States)

^b Woodmont Office Center II   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; PEGADEMASE; PEGALDESLEUKIN; PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; CIRCADIAN RHYTHM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

ABSORPTION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION; HUMANS; KIDNEY; LIVER; POLYETHYLENE GLYCOLS; PROTEINS; RECOMBINANT PROTEINS;

EID: 18644361997     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544040-00001     Document Type: Review

References (88)

1. Marderosian AHD, Kroll DJ. Biotechnology and drugs. In: Gennaro AR, editor. Remington: the science and practice of pharmacy. 20th ed. Baltimore (PA): Lippincott Williams and Wilkins, 2000: 944-62
2. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid ER, editor. Peptides and protein drug analysis. New York: Marcel Dekker Inc., 2000: 633-69
3. Rodwell VW. Proteins: structure and function. In: Murray RK, Granner DK, Mayes PA, et al., editors. Harper's biochemistry. 23rd ed. Norwalk (CT): Appleton and Lange, 1993: 41-8
4. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 419-29
5. Drickamer K, Taylor ME. Evolving views of protein glycosylation. Trends Biochem Sci 1998; 23: 321-4
6. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weight after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6
7. Yoshimaga Y, Harris JM. Effects of coupling chemistry on activity of polyethylene glycol-mediated enzyme. J Bioact Compat Polyn 1989; 4: 17-24
8. Chen SA, Sawchuk RJ, Brundage RC, et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 2000; 293: 248-59
9. Drickamer K, Taylor ME. Evolving views of protein glycosylation. Trends Biochem Sci 1998; 23: 321-4
10. Jaeken J, Metthijs G. Congenital disorders of glycosylation. Annu Rev Genomics Hum Genet 2001; 2: 129-51
11. Steen PVD, Rudd PM, Dwek RA, et al. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 1999; 33: 151-208
12. Martin-Rendon E, Blake DJ. Protein glycosylation in disease: new insights into the congenital muscular dystrophies. Trends Pharmacol Sci 2003; 24: 178-83
13. Hovgaard D, Mortensen BT, Schifter S, et al. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993; 50: 32-6
14. Buckel P. Recombinant proteins for therapy. Trends Pharmacol Sci 1996; 17: 450-6
15. Toon S. The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 1996; 21: 93-103
16. Ferraiolo BL, Mohler MA. Goals and analytical methodologies for protein disposition studies. In: Ferraiolo BL, Mohler MA, Gloff CA, editors. Protein pharmacokinetics and metabolism. New York: Plenum Press, 1992: 1-21
17. Lee JW, Colburn WA. Immunoassay techniques. In: Ohannesian L, Streeter AJ, editors. Handbook of pharmaceutical analysis. New York: Marcel Dekker Inc., 2002: 225-312
18. Randall CS, Malefyt TR, Sternson LA. Approaches to the analysis of peptides. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc., 1991: 203-46
19. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH): I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril 1994; 61: 669-78
20. Wills RJ, Dennis S, Spiegel HE, et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharm Ther 1984; 35: 722-7
21. Ferraiolo BL, Fuller GB, Burnett B, et al. Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous and subcutaneous administration. J Biol Response Mod 1988; 7: 115-22
22. Kurzrock R, Rosenblum MG, Sherwin SA, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 1985; 45: 2866-72
23. Radwanski E, Perentesis G, Jacobs S, et al. Pharmacokinetics of interferon α-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432-5
24. Supersaxo A, Hein WR, Steifen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 2: 167-9
25. Supersaxo A, Hein W, Gallati H, et al. Recombinant human Interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 1988; 8: 472-6
26. Jones JM, Macdougall IC, Robinson MI, et al. Subcutaneous recombinant erythropoietin therapy: comparison of 3 different sites of injection. J Am Soc Nephrol 1990; 1: 400
27. Laursen T, Jorgensen JO, Christiansen JS. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clin Endocrinol (Oxf) 1994; 40: 373-8
28. Mohler MA, Cook JE, Baumann G. Binding proteins of protein therapeutics. In: Ferraiolo BL, Mohler MA, Gloff CA, editors. Protein pharmacokinetics and metabolism. New York: Plenum Press, 1992: 35-71
29. Baumann G, Amburn K, Shaw MA. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 1988; 122: 976-84
30. Havredaki M, Barona F. Variations in interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn J Med Sci Biol 1985; 38: 107-11
31. Femandez-Botran R, Vitetta ES. A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc Natl Acad Sci U S A 1990; 87: 4202-6
32. Lelchuk R, Playfair JHL. Serum IL-2 inhibitor in mice: I. Increase during infection. Immunology 1985; 56: 113-8
33. Malik S, Lantz M, Slevin M, et al. Infusion of recombinant human tumour necrosis factor (rhTNF) causes an increase in circulating TNF-binding protein in man [abstract]. Int J Exp Pathol 1991; 72: A6
34. Garzone PD. Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules. In: Atkinson AJ, Daniels CE, Dedrick RL, et al., editors. Principles of clinical pharmacology. San Diego (CA): Academic Press, 2001: 401-18
35. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15
36. Kompella A, Lee VHL. Pharmacokinetics of peptide and protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc., 1991: 391-484
37. Takakura Y, Fujita T, Hashida M, et al. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990; 7: 339-46
38. Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 1979; 16: 251-70
39. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Deliv Rev 1990; 4: 149-69
40. Maack T. Renal handling of low molecular weight proteins. Am J Med 1975; 58: 57-64
41. Ganapathy V, Leibach FH. Carrier-mediated reabsorption of small peptides in renal proximal tubule. Am J Physiol 1986; 251 (6 Pt 2): F945-53
42. Van Griensven JM, Burggraaf KJ, Gerloff J, et al. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995; 57: 381-9
43. Van Griensven JM, Huisman LG, Stuurman T, et al. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60: 504-11
44. Kuwabara T, Uchimura T, Takai K, et al. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. J Pharmacol Exp Ther 1995; 273: 1114-22
45. Preusch PC. Equilibrative and concentrative drug transport mechanisms. In: Atkinson AJ, Daniels CE, Dedrick RL, et al., editors. Principles of clinical pharmacology. San Diego (CA): Academic Press, 2001: 201-22
46. LaRusso NF. Proteins in bile: how they get there and what they do. Am J Physiol 1984; 247 (3 Pt 1): G199-205
47. Kaplan SL, August GP, Blethen SL, et al. Clinical studies of recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1986; I: 697-700
48. Spiegel RJ, Spicehandler JR, Jacobs SL, et al. Low incidence of neutralizing factors in patients receiving recombinant-alpha-2b-interferon (Intron-A). Am J Med 1986; 80: 223-8
49. Fineberg S, Galloway J, Fineberg N, et al. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983; 25: 465-9
50. Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. A phase I study of recombinant interleukin-2 plus recombinant beta-interferon. Cancer Res 1988; 48: 3875-81
51. Konrad M, Childs A, Merigan T, et al. Assessment of the antigenic response in humans to a recombinant Interferon beta. J Clin Immunol 1987; 7: 365-75
52. Working PK. Potential effects of antibody induction by protein drugs. In: Ferraiolo BL, Mohler MA, Gloff CA, editors. Protein pharmacokinetics and metabolism. New York: Plenum Press, 1992: 73-92
53. Itri LM, Sherman MI, Paleroni A, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha-2. J Interferon Res 1989; 9 Suppl. 1: S9-15
54. Marafino BJ, Kopplin JR. Chracterization of the toxicity profile. In: VHL Lee, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc., 1991: 807-29
55. Davis FF, Kazo GM, Nucci ML, Abuchowski A. Reduction of immunogenicity and extension of circulating half-life of peptides and proteins. In: VHL Lee, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc., 1991: 831-64
56. Queseda JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J Natl Cancer Inst 1983; 70: 1041-6
57. Queseda JR, Rios A, Swanson D, et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal carcinoma. J Clin Oncol 1985; 3: 1522-8
58. Rosenblum MG, Unger BW, Gutterman JU, et al. Modification of human leucocyte interferon pharmacology with monoclonal antibody. Cancer Res 1985; 45: 2421-4
59. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1999; 64: 412-23
60. Waldhausal WK, Bratusch-Marrain PR, Vierhapper H, et al. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism 1983; 32: 478-86
61. Hindmarsh PC, Matthews OR, Brain CE, et al. The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostattn. Clin Endocrinol 1989; 30: 443-50
62. Van Cauter E, Refetoff S. Multifactorial control of the 24-hour secretory profiles of pituitary hormones. J Endocrinol Invest 1985; 8: 381-91
63. Baxter RC, Cowell CT. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432-40
64. Dominguez Rodriguez A, Abreu Gonzalez P, Garcia MJ, et al. Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction. Rev Esp Cardiol 2003; 56: 555-60
65. Gavrila A, Peng CK, Chan JL, et al. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and Cortisol patterns. J Clin Endocrinol Metab 2003; 6: 2838-43
66. Hulse JA, Rosenthal SM, Cutler L, et al. The effect of pulsatile administration, continuous infusion and diurnal variation on the growth hormone response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 1986; 63: 872-8
67. Tarn CS, Heersche JNM, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982; 110: 506-12
68. Klabunde RE, Burke SE, Henkin J. Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb Res 1990; 58: 511-7
69. Clark RG, Jansson JO, Isaksson O, et al. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol 1985; 104: 53-61
70. Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypophthalamic gonadotropin-releasing hormone. Science 1978; 202: 631-3
71. Vaage J, Pauly JL, Harlos JP. Influence of the administration schedule on the therapeutic effect of interleukin-2. Int J Cancer 1987; 39: 530-3
72. Levy G. Kinetics of pharmacologic effects. Clin Pharmacol Ther 1966; 7: 362-72
73. Wagner JG. Kinetics of pharmacologic response: I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968; 20: 173-201
74. Childs A, Grovel J, Baron DA, et al. Population PK/PD of tissue factor pathway inhibitor (TFPI) in cynomolgous monkeys during a 12-day toxicology study. Fundam Appl Toxicol 1996; 30 Suppl. 1: 104
75. Schaub R, Garzone P, Bouchard P, et al. Preclinical studies of recombinant factor DC. Semin Hematol 1999; 35 Suppl. 2: 28-32
76. Ramakrishnan R, Cheung WK, Farrell F, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 2003; 306: 324-31
77. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003; 31: 510-8
78. Furchgott RF. The pharmacology of vascular smooth muscle. Pharmacol Rev 1955; 7: 183-265
79. Hull CJ, Van Beem HB, McLeod K, et al. A pharmacodynamic model for pancuronium. Br J Anaesth 1978; 50: 1113-23
80. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71
81. Hooper S. Pharmacokinetics and pharmacodynamics of intravenous regular human insulin. In: Garzone PD, Colbum WA, Mokotoff M, editors. Pharmacokinetics and pharmacodynamics: peptides, peptoids, and proteins. Cincinnati (OH): Harvey Whitney Books, 1991: 128-37
82. Woodworth JR, Howey DC, Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care 1994; 17: 64-9
83. Porchet HC, Cotonner J-Y, Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone: III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril 1994; 61: 687-95
84. Ariens EJ, editor. Molecular pharmacology: the mode of action of biologically active compounds. New York: Academic Press, 1964
85. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78
86. Fiscitelli Sc, Forrest A, Vogel S, et al. A novel PK/PD model for infused interleukin-2 (IL-2) in HIV-infected patients [abstract]. 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1996 Mar 20-22; Florida
87. Nieforth KA, Nadeau R, Patel IH, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of Interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996; 59: 636-46
88. Lee H, Kimko HC, Rogge M, et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003; 73: 348-65